Atherosclerosis, heart and blood vessel disease Atherosclerosis
Conditions
Interventions
None listed
Sponsors
Amsterdam UMC
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: In order to be eligible to participate in this study in the elevated Lp(a) subgroup, a subject must meet all of the following criteria: • Man or woman >=50 years of age; • Lp(a) level >= 125 nmol/L; • Identified as having elevated Lp(a) through Lp(a) family cascade screening at the Amsterdam UMC Vascular Medicine outpatient clinic; • Able and willing to provide informed consent; • Able to comply with study requirements. In order to be eligible to participate in this study in the control subgroup, a subject must meet all of the following criteria: • Man or woman >=50 years of age; • Lp(a) level < 50 nmol/L; • Able and willing to provide informed consent; • Able to comply with study requirements.
Exclusion criteria
Exclusion criteria: A potential subject who meets any of the following criteria will be excluded from participation in this study (both subgroups): • Renal insufficiency, defined as eGFR < 30 ml/min • History of ASCVD (acute coronary syndrome, history of myocardial infarction, stable or unstable angina pectoris or coronary or other arterial revascularization, stroke, or peripheral artery disease including aortic aneurysm, all of atherosclerotic origin) • History of atrial fibrillation (excluding paroxysmal atrial fibrillation) • Any other treatment or clinically relevant condition that could interfere with the conduct or interpretation of the study in the opinion of the investigator • Unable or unwilling to provide informed consent • Unable to comply with study requirements.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The main study parameter is the presence of coronary plaque measured via CCTA. | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary parameters include the presence of obstructive stenosis, total coronary plaque volumes, calcified and non-calcified plaque volumes, low-attenuation plaque, pericoronary adipose tissue attenuation, high risk plaque features, and the CAD-RADS classification. | — |
Countries
Netherlands
Contacts
Public ContactM.E. Annink
Amsterdam UMC
Outcome results
None listed